Effect of SARS-CoV-2 vaccination on severity and outcome of COVID-19 among health-care workers of a tertiary care hospital in India

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL
R. Gaind, N. Gupta, Ravindra Nath, Nilushree Srivastava, Tanushree Gahlot, P. Ish, Nitesh Gupta
{"title":"Effect of SARS-CoV-2 vaccination on severity and outcome of COVID-19 among health-care workers of a tertiary care hospital in India","authors":"R. Gaind, N. Gupta, Ravindra Nath, Nilushree Srivastava, Tanushree Gahlot, P. Ish, Nitesh Gupta","doi":"10.4103/injms.injms_56_22","DOIUrl":null,"url":null,"abstract":"Introduction: SARS-CoV-2 vaccines decrease the risk of infection. However, data on the utility of vaccines in decreasing the severity of COVID-19 need to be evaluated. This study was carried out with the primary objective to assess the severity and clinical outcome of COVID-19 infections among unvaccinated and vaccinated health-care workers (HCWs). Methods: This was a hospital-based retrospective cohort study including all HCWs who developed microbiologically confirmed COVID-19 over 6 months from January 31, 2021, to July 31, 2021 (during the second wave of COVID-19 in India). Data were recorded through a questionnaire which included demographic details, primary location of work, history of vaccination with dates, comorbidities, severity of COVID-19, and outcome. HCWs who tested positive for SARS-CoV-2 before any dose of the COVID-19 vaccine were included in the “unvaccinated” group. Whereas HCWs who developed SARS-CoV-2 after a single or both doses of vaccine were included in the vaccinated group. The outcome and mortality among the vaccinated and unvaccinated groups were evaluated and compared. Results: The study included 500 HCWs who developed a microbiologically confirmed CVOID-19 infection. It was a predominantly middle-aged population with 247 unvaccinated and 253 vaccinated at the time of developing COVID-19. Only one-fourth of the population (26%) was working in the COVID-19 area and the source of COVID-19 to most was either a COVID-19 patient (39%) or a colleague (38%). Around 13% of the population had comorbidities with cardiovascular disease and diabetes being the most common. The majority of the patients were mild (71%) and most were treated at home in isolation (91%). Only 4% of the study population required intensive care. Among the vaccinated group, COVID-19 infection was predominantly mild and this difference was statistically significant as compared to the nonvaccinated. No difference was found in mortality among the two groups; however, the overall mortality was only 1%. Conclusions: SARS-CoV-2 vaccines reduce the severity of COVID-19 besides preventing infections and its spread. This can help in effective care of COVID-19 in home isolation without overburdening the health-care services. More studies including clinical parameters and microbiological components are required to understand the true extent of this protection of vaccines from severe forms of COVID-19.","PeriodicalId":43811,"journal":{"name":"Indian Journal of Medical Specialities","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Specialities","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/injms.injms_56_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: SARS-CoV-2 vaccines decrease the risk of infection. However, data on the utility of vaccines in decreasing the severity of COVID-19 need to be evaluated. This study was carried out with the primary objective to assess the severity and clinical outcome of COVID-19 infections among unvaccinated and vaccinated health-care workers (HCWs). Methods: This was a hospital-based retrospective cohort study including all HCWs who developed microbiologically confirmed COVID-19 over 6 months from January 31, 2021, to July 31, 2021 (during the second wave of COVID-19 in India). Data were recorded through a questionnaire which included demographic details, primary location of work, history of vaccination with dates, comorbidities, severity of COVID-19, and outcome. HCWs who tested positive for SARS-CoV-2 before any dose of the COVID-19 vaccine were included in the “unvaccinated” group. Whereas HCWs who developed SARS-CoV-2 after a single or both doses of vaccine were included in the vaccinated group. The outcome and mortality among the vaccinated and unvaccinated groups were evaluated and compared. Results: The study included 500 HCWs who developed a microbiologically confirmed CVOID-19 infection. It was a predominantly middle-aged population with 247 unvaccinated and 253 vaccinated at the time of developing COVID-19. Only one-fourth of the population (26%) was working in the COVID-19 area and the source of COVID-19 to most was either a COVID-19 patient (39%) or a colleague (38%). Around 13% of the population had comorbidities with cardiovascular disease and diabetes being the most common. The majority of the patients were mild (71%) and most were treated at home in isolation (91%). Only 4% of the study population required intensive care. Among the vaccinated group, COVID-19 infection was predominantly mild and this difference was statistically significant as compared to the nonvaccinated. No difference was found in mortality among the two groups; however, the overall mortality was only 1%. Conclusions: SARS-CoV-2 vaccines reduce the severity of COVID-19 besides preventing infections and its spread. This can help in effective care of COVID-19 in home isolation without overburdening the health-care services. More studies including clinical parameters and microbiological components are required to understand the true extent of this protection of vaccines from severe forms of COVID-19.
印度一家三级护理医院医护人员接种SARS-CoV-2疫苗对新冠肺炎严重程度和结果的影响
引言:严重急性呼吸系统综合征冠状病毒2型疫苗可降低感染风险。然而,需要评估疫苗在降低新冠肺炎严重程度方面的效用数据。本研究的主要目的是评估未接种疫苗和接种疫苗的医护人员(HCW)中新冠肺炎感染的严重程度和临床结果。方法:这是一项基于医院的回顾性队列研究,包括2021年1月31日至2021年7月31日(在印度第二波新冠肺炎期间)6个月内发生微生物确诊的新冠肺炎的所有HCW。数据通过问卷记录,其中包括人口统计详细信息、主要工作地点、接种史和日期、合并症、新冠肺炎严重程度和结果。在接种任何一剂新冠肺炎疫苗之前,SARS-CoV-2检测呈阳性的医务人员被纳入“未接种疫苗”组。而在单剂或两剂疫苗接种后出现严重急性呼吸系统综合征冠状病毒2型的HCW被纳入接种组。对接种疫苗组和未接种疫苗组的结果和死亡率进行了评估和比较。结果:该研究包括500名经微生物证实感染CVOID-19的HCW。这是一个以中年人口为主的群体,在发展为新冠肺炎时,247人未接种疫苗,253人接种疫苗。只有四分之一的人口(26%)在新冠肺炎地区工作,大多数人的新冠肺炎来源是新冠肺炎患者(39%)或同事(38%)。大约13%的人口患有合并症,其中心血管疾病和糖尿病最为常见。大多数患者病情较轻(71%),大多数患者在家接受隔离治疗(91%)。只有4%的研究人群需要重症监护。在接种疫苗的人群中,新冠肺炎感染主要是轻微的,与未接种疫苗的人相比,这一差异具有统计学意义。两组的死亡率没有差异;但总死亡率仅为1%。结论:SARS-CoV-2疫苗除了预防感染和传播外,还能降低新冠肺炎的严重程度。这有助于在家隔离的情况下有效护理新冠肺炎,而不会使医疗服务负担过重。需要进行更多的研究,包括临床参数和微生物成分,以了解疫苗对严重形式的新冠肺炎的真正保护程度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Indian Journal of Medical Specialities
Indian Journal of Medical Specialities MEDICINE, GENERAL & INTERNAL-
自引率
16.70%
发文量
51
期刊介绍: The Indian Journal of Medical Specialities is an all-encompassing peer-reviewed quarterly journal. The journal publishes scholarly articles, reviews, case reports and original research papers from medical specialities specially pertaining to clinical patterns and epidemiological profile of diseases. An important highlight is the emphasis on undergraduate and postgraduate medical education including various aspects of scientific paper-writing. The journal gives priority to research originating from the developing world, including from the tropical regions of the world. The journal also publishes special issues on health topics of current interest. The Indian Journal of Medical Specialities is one of the very few quality multispeciality scientific medical journals.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信